Ischemic optic neuropathy
Drug research and approvals for ischemic optic neuropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 14 studies of ischemic optic neuropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 4 open orphan designations naming it.
- Recruiting worldwide: 14
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During RhinoplastyNCT07832305 · Not applicable · Hitit University · starts Sep 20, 2026
- Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic…NCT07453888 · Phase 3 · Dompé Farmaceutici S.p.A · starts Jul 1, 2026
- Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve…NCT07290244 · Phase 1 · Life Biosciences Inc. · starts Mar 2, 2026
- Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell ArteritisNCT07206238 · Not reported · Copenhagen University Hospital, Rigshospitalet · starts Jan 14, 2026
- Optic Nerve Injury in Obstructive Sleep Apnea PatientsNCT06748703 · Not applicable · Nanjing Medical University · starts Jan 1, 2025
- Visual Involvement in Giant Cell ArteritisNCT06500728 · Not reported · ASST Fatebenefratelli Sacco · starts Jun 27, 2024
- Early Percutaneous Transluminal Angioplasty in Diabetic Foot Syndrome (PTA-DFS)NCT06124586 · Not applicable · Heinrich-Heine University, Duesseldorf · starts Feb 1, 2024
- Optic Nerve Sheath Ultrasound in Giant Cell ArteritisNCT05749094 · Not reported · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · starts Aug 9, 2025
- Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAIONNCT05147701 · Phase 1 · The Foundation for Orthopaedics and Regenerative Medicine · starts Feb 1, 2022
Phase 3 3
- BosentanEndothelin receptor, ET-A/ET-B antagonist
- Triamcinolone acetonideGlucocorticoid receptor agonist
- OxygenEssential for cellular homeostasis
Phase 2 3
- BevacizumabVascular endothelial growth factor A inhibitor
- AlprostadilProstanoid EP1 receptor agonist
- Epoetin betaErythropoietin receptor agonist
Phase 1 or earlier 4
- RanibizumabVascular endothelial growth factor A inhibitor
- TimololBeta-1 adrenergic receptor antagonist
- TriamcinoloneGlucocorticoid receptor agonist
- Ciliary neurotrophic factor
How its trials ended
46 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 7 whose ending is known, 43% met their primary endpoint, 0% missed it and 57% stopped early.
- Completed, result not reported2043%
- Status unknown1124%
- Ongoing817%
- Met its primary endpoint37%
- Stopped: other or unclear24%
- Stopped: enrollment or feasibility12%
- Stopped: sponsor or business decision12%
| Jul 26, 2021 | 19 amino acid synthetic peptide NOS-enhancerTreatment of anterior ischemic optic neuropathy | Biozeus Biopharmaceutical SA | Designated |
| Dec 26, 2017 | NP-CSIC002Treatment of anterior ischemic optic neuropathy (AION) | Neurizon Pharma | Designated |
| Sep 25, 2012 | Synthetic double-stranded siRNA oligonucleotide directed…Treatment of ischemic optic neuropathy | Quark Pharmaceuticals, Inc. | Designated |
| Feb 7, 2000 | BrimonidineTreatment of anterior ischemic optic neuropathy. | AbbVie | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA